Despite significant clinical advances, CAR-T therapies continue to face critical limitations, including rapid T-cell exhaustion, mitochondrial dysfunction, and metabolic suppression imposed by the nutrient-deprived tumor microenvironment. Our Targeted Nutrient Supplementation (L-Arginine) for CAR-T Metabolic Fuel platform integrates clinically adaptable ex vivo arginine priming with advanced genetic engineering strategies to optimize CAR-T cellular metabolism and nutrient autonomy. By enhancing mitochondrial fitness and enabling sustained function under stress, we empower you to develop next-generation CAR-T products with superior persistence, central memory characteristics, and robust anti-tumor efficacy.
The metabolic fitness of CAR-T cells is a critical determinant of their antitumor efficacy and persistence. Thus, targeted nutrient supplementation has gained traction as a strategic approach to bolster cellular metabolism, thereby enhancing therapeutic outcomes. L-Arginine, a semi-essential amino acid with pleiotropic roles in T cell activation, proliferation, and mitochondrial bioenergetics, has emerged as a key metabolic fuel for CAR-T cells.
Fig.1 Metabolic priming of CAR‑T cells via targeted L‑Arginine supplementation.
Creative Biolabs offers a specialized platform designed to enhance the metabolic resilience of CAR-T cells by refining their intrinsic energy utilization pathways. We generate T cell products that have been metabolically reprogrammed to favor oxidative phosphorylation over transient glycolytic activity. This metabolic shift enables therapeutic candidates not only to reach tumor sites but also to sustain effector function and persistence within nutrient-limited microenvironments.
We offer two complementary strategies to overcome arginine limitation in CAR-T therapy: a clinical-stage ex vivo supplementation protocol to preserve metabolic fitness under stress, and a next-generation engineering platform enabling autonomous arginine synthesis for sustained function within the nutrient-deprived tumor microenvironment.
Final Deliverables:
Q1: How does L-Arginine supplementation differ from standard cytokine expansion?
A1: Standard cytokines drive T cell expansion primarily through activation pathways, which can accelerate differentiation and contribute to functional exhaustion over time. L-Arginine supplementation targets the underlying metabolic infrastructure, steering cellular energy production toward oxidative phosphorylation. This shift supports prolonged survival, facilitates memory formation, and promotes sustained effector function without overstimulating the cells.
Q2: Will high L-Arginine concentrations cause toxicity?
A2: We apply precisely calibrated dosing strategies to maintain L-Arginine levels within an optimal intracellular range. Our protocols include comprehensive quality controls that assess cell viability, phenotypic stability, and functional integrity throughout the process. This ensures that metabolic benefits are achieved without inducing toxicity, off-target effects, or unintended alterations to T cell behavior.
Creative Biolabs offers more than conventional cell expansion by providing a distinct advantage rooted in metabolic armoring. While standard manufacturing often relies on high-glucose conditions that may compromise T-cell fitness, we leverage established insights into L-arginine sensing pathways to generate cells with enhanced metabolic resilience. Our platform integrates proteomics, metabolomics, and synthetic biology to achieve this refined functional outcome.
"Applying Creative Biolabs' metabolic optimization strategy in our work allowed us to sustain a central memory phenotype across the manufacturing process, effectively addressing the metabolic instability previously observed in clinical settings." Dr. Al*** J.
"Incorporating targeted nutrient supplementation markedly extended CAR-T survival in acidic tumor microenvironment models, with OXPHOS-driven persistence proving superior to standard culture conditions." Prof. Ma*** S.
"Using L-arginine as a metabolic modulator enabled us to lower PD-1 expression in effector cells, supporting sustained anti-tumor activity in high-burden mouse models." Dr. Ri*** L.
We invite you to explore how our arginine-based metabolic optimization platform can overcome the persistence and efficacy barriers in your CAR-T programs. Contact us today to discuss customized solutions that advance your next-generation cell therapy candidates.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION